References
- Stone, R. : NIH fends off critics of tamoxifen study. Science 258, 734 (1992) https://doi.org/10.1126/science.1359643
- Powles, T. J. : The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet. 340, 1145 (1992) https://doi.org/10.1016/0140-6736(92)93162-G
- Jaiyesirni, I. A. Buzdar, A. U. Decker, D. A. and Hortobagyi, G. N. : Use of tamoxifen for breast cancer: twenty-eight years later. J Clin. Oncol. 13, 513 (1995) https://doi.org/10.1200/JCO.1995.13.2.513
- Robinson, E. Kimmick, G. G. and Muss, H. B. : Tamoxifen in postmenopausal women a safety perspective. Drugs Aging. 8, 329 (1996) https://doi.org/10.2165/00002512-199608050-00002
- Swenberg, J. A. : Clinical relevance of laboratory and animal data on tamoxifen. Oncology (Huntingt) 11, 39 (1997)
- Buckley, M. T. and Goa, K L. : Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin. Pharmacokin. 37, 451 (1989)
- Lim, C. K. Yuan, Z. X. Lamb, J. H. White, I. N. H. De Matteis, F. and Smith, L. L. : A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis. 15, 589 (1994) https://doi.org/10.1093/carcin/15.4.589
- Jacolot, F., Simon, I., Dreano, I., Beaune, P., Riche, C. and Berthou, F. : Identification of the cytochrome P450 IIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41, 1911 (1991) https://doi.org/10.1016/0006-2952(91)90131-N
- Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A. and Kupfer, D. : Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21, 645 (1993)
- Mani, C., Pearce, R., Parkinson, A. and Kupfer, D. : Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis. 15, 2715 (1994) https://doi.org/10.1093/carcin/15.12.2715
- Berthou, F., Dreano, Y., Belloc, C., Kangas, L., Gautier, J. C. and Beaune, P. : Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol. 47, 1883 (1994) https://doi.org/10.1016/0006-2952(94)90319-0
- Dehal, S. S. and Kupfer, D. : Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug. Metab. Dispos. 27, 681 (1999)
- Simon, I., Berthou, F., Riche, C., Beaune, P. and Ratanasavanh, D. : Both cytochromes P4501Al and 3A4 are involved in the N-demethylation of tamoxifen, In: Proceedings of the Fifth European ISSX Meeting Tours, France, Abstract No. 44 (1993)
- Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A. and Kupfer, D. : Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 21, 645 (1993)
- Crewe, H. K., Ellis, S. W., Lennard, M. S. and Tucker, G. T. : Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171 (1997) https://doi.org/10.1016/S0006-2952(96)00650-8
- Daniel, P. C., Gaskell, J., Bishop, H., Campbell, C. and Nicholson, R. : Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma. Eur. J. Cancer Clin. Oncol. 17, 1183 (1981) https://doi.org/10.1016/S0277-5379(81)80022-3
- Jordan, V. C., Collins, M. M., Rowsby, L. and Prestwich, G. : A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305 (1977) https://doi.org/10.1677/joe.0.0750305
- DeGregorio, M. W., Coronado, E. and Osborne, C. K. : Tumor and serum tamoxifen concentrations in the athymic nude mice. Cancer Chemother. Pharmacol. 23, 68 (1989) https://doi.org/10.1007/BF00647244
- Robinson, S. P., Langan-Fahey, S. M. and Jordan, V. C. : Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur. J. Cancer Clin. Oncol. 25, 1769 (1989) https://doi.org/10.1016/0277-5379(89)90347-7
- Gant, T. W., O'Connor, C. K., Corbitt, R., Thorgeirsson, U. and Thorgeirsson, S. S. : In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol. 133, 269 (1995) https://doi.org/10.1006/taap.1995.1151
- Rao, U. S., Fine R. L. and Scarborough, G. A. : Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem. Pharmacol. 48, 287 (1994) https://doi.org/10.1016/0006-2952(94)90099-X
- Thiebaut, F., Tsuruo, T., Hamada, H., Cottesman, M. M., Pastan, I. and Willingham, M. C. : Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84, 7735 (1987)
- Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R. and Bertino, J. R. : Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86, 695 (1989)
- Sugawara, I., Kataoka, I., Morishita, Y., Hamada, H., Tsuruo, T., Itoyama, S. and Mori, S. : Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 48, 1926 (1988)
- Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993) https://doi.org/10.1146/annurev.bi.62.070193.002125
- Gan, L.-S. L., Moseley, M. A., Khosla, B., Augustijns, P. E, Bradshaw, T. P., Hendren, R. W. and Thakker, D. R. : CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344 (1996)
- Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1996) https://doi.org/10.1016/S0169-409X(97)00041-0
- Wacher, V. H., Silverman, J. A., Zhang, Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of pep tides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998) https://doi.org/10.1021/js980082d
- Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999) https://doi.org/10.1023/A:1018872207437
- Reynolds, J. E. F. : Martindale - The Extra Pharmacopeia, Pharmaceutical Press. London (1993)
- Krikler, D. M. and Spurrell, R. A. : Verapamil in the treatment of paroxysmal supraventricular tachycardia. Postgrad. Med. J. 50, 447 (1974) https://doi.org/10.1136/pgmj.50.585.447
- Gould, B. A., Mann, S., Kieso, H., Subramanian, V. B. and Raftery, E. B. : The 24-hour ambulatory blood pressure profile with verapamil. Circulation 65, 22 (1982) https://doi.org/10.1161/01.CIR.65.1.22
- Lewis, G. R., Morley, K. D., Lewis, B. M. and Bones, P. J. : The treatment of hypertension with veraparnil, N. Z. Med. J. 87, 351 (1978)
- Leveque, D. and Jehl, F. : P-glycoprotein and pharmacokinetics. Anticancer Res. 15, 331 (1995)
- Burton, P. S., Conradi, R. A., Hilgers, A. R. and Ho, N. F. : Evidence for a polarized efflux for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190, 760 (1993) https://doi.org/10.1006/bbrc.1993.1114
- Hunter, J., Jepson, M. A., Tsuruo, T., Simmons, N. L. and Hirst, B. H. : Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. BioI. Chem. 268, 14991 (1993)
- Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M. and McLeod, H. L. : Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44, 279 (2005) https://doi.org/10.2165/00003088-200544030-00005
- Magnarin, M., Morelli, M., Rosati, A., Bartoli, F., Candussio, L., Giraldi, T. and Decorti. G. : Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PKI cells. Eur. J. Pharmacol. 483, 19 (2004) https://doi.org/10.1016/j.ejphar.2003.10.010
- Choi, J. S. and Kim, H. J. : Pharmacokinetic interaction between diltiazem and paclitaxel in rats. J. Kor. Pharm. Soc. 33, 299 (2003)
- Choi J. S. and Lee, C. K. : Pharmacokinetic interaction between nifedipine and paclitaxel in rats. J. Pharm. Soc. Korea 48, 61 (2004)
- Scambia, G., Ranelletti, F.O., Panici, P. B., De Vincenzo, R., Bonanno, G., Frrandina, G., Paiantelli, M., Bussa, S., Rumi, C. and Cianfriglia, M. et al. : Quercetin potentiates the effect of adriamycin in a multidurg-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 36, 459 (1994) https://doi.org/10.1007/BF00685794
- Choi, J. S., Jo, B. W. and Kim, Y. C. : Enhanced bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J Pharm. Biopharm. 57, 313 (2004) https://doi.org/10.1016/j.ejpb.2003.11.002
- Zhang, H., Wong, C. W., Coville P. F. and Wanwimolruk, S. : Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Metabol. Drug Interact. 17, 351 (2000)
- Candussio, L., Decorti, G., Crivellato, E., Granzotto, M., Rosati, A., Giraldi, T. and Bartoli, F. : Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin. Life Sci. 71, 3109 (2002) https://doi.org/10.1016/S0024-3205(02)02175-6
- Kerr, D. J., Graham, J., Cummings, J., Morrison, J. G., Thompson, G. G., Brodie, M. J. and Kaye, S. B. : The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol. 18, 239 (1986)
- Fried, K. M. and Wainer, I. W. : Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl. 655, 261 (1994) https://doi.org/10.1016/0378-4347(94)00054-9
- Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine 16, 203 (1983) https://doi.org/10.1016/0010-468X(83)90082-X
- Choi, J. S. and Li, X. : The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur. J. Pharm. Sci. 24, 95 (2005) https://doi.org/10.1016/j.ejps.2004.10.002
- Verschraagen, M., Koks, C. H., Schellens, J. H. and Beijnen, J. H. : P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res. 40, 301 (1999) https://doi.org/10.1006/phrs.1999.0535
- Hotta, T., Tanimura, H., Yamaue, H., Iwahashi, M., Tani, M., Tsunoda, T., Tarnai, M., Noguchi, K., Mizobata, S., Arii, K. and Terasawa, H. : Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J. Surg. Res. 66, 31 (1996) https://doi.org/10.1006/jsre.1996.0368
- Shao, Y. M., Ayesh, S. and Stein, W. D. : Mutually co-operative interactions between modulators of P-glycoprotein. Biochim. Biophys. Acta. 1360, 30 (1997) https://doi.org/10.1016/S0925-4439(96)00065-8